Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: rituximab

FDA Issues Boxed Warning for Hydroxyurea & Neutropenia May Occur after Rituximab Treatments

Michele B. Kaufman, PharmD, BCGP  |  August 26, 2015

The FDA has issued a new boxed warning for Droxia (hydroxyurea). Also, according to a new study, RA patients receiving rituximab should be monitored for late-onset neutropenia…

Filed under:Biologics/DMARDsDrug Updates

Hepatitis Reaction with Rituximab Sparks Drug Safety Alert

M.J. Burton, MD, K.L. Winthrop, MD, MSPH, & J.W. Baddley, MD, MPH  |  January 1, 2015

The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation

Filed under:Biologics/DMARDsDrug Updates Tagged with:drugFDAhepatitisrheumatologyrituximabSafetyvirus

ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis

Mary Beth Nierengarten  |  February 1, 2013

Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists

Filed under:ConditionsDrug UpdatesVasculitis Tagged with:ANCA-Associated VasculitiscyclophosphamiderituximabTreatment

Highlights from the European Congress of Internal Medicine

Vanessa Caceres  |  July 10, 2025

An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.

Filed under:ConditionsMeeting ReportsOther Rheumatic ConditionsSystemic Lupus Erythematosus Tagged with:abataceptCAR-T cell therapyEuropean Congress of Internal MedicineGiant Cell ArteritisGlucocorticoidsInterstitial Lung DiseaseMethotrexatenintedanibPolymyalgia Rheumaticarituximabserological testingstem cell transplantationSystemic sclerosis

Rheumatology in China: An American Fellow’s Experience

Audrey Liu, MD  |  July 9, 2025

An American rheumatology fellow explores the differences& similarities between the U.S. & Chinese health systems through a visit toa hospital inHangzhou, China.

Filed under:OpinionPractice Support Tagged with:Access to carecost of health careFellowsFellows Forumglobal healthhealthcare policyhealthcare systems comparisonmedical educationrheumatology in China

ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting

From the College  |  June 23, 2025

An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:ACR advocacyAMA House of Delegates (HOD)

B Cell-Depleting Therapy in SLE & Lupus Nephritis

Katie Robinson  |  May 31, 2025

“B cells are central orchestraters of autoimmune disease by contributing to autoantibody production, antigen presentation and cytokine production,” says Georg Schett, MD, head of the Department of Medicine 3 (Rheumatology and Immunology) of the Friedrich-Alexander University Erlangen-NĂĽrnberg, Germany. “B cells can be inhibited by monoclonal antibodies and chimeric antigen receptor (CAR) expressing cells.” Dr. Schett…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:B cell depleting therapyB cell depletionCAR-T cell therapyCD19 CAR-T cell treatmentLupus nephritis supplement

Underwater Biosimilars Coalition Shares Results of Practice Survey with Congressional Leaders

From the College  |  May 16, 2025

This week, the Coalition sent Congressional leadership a letter detailing the results of a recent survey about how underwater biosimilars are impacting physicians’ ability to provide high-quality care. Almost all of the nearly 200 practices queried reported being  underwater on several biosimilars, with rituximab and infliximab biosimilars being the most common.

Filed under:InsuranceLegislation & AdvocacyPractice Support Tagged with:ACR advocacyBiosimilars

Editor's Pick

Large International Study Says Flares Rare After COVID Vaccination

Catherine Kolonko  |  April 3, 2025

‘Patients with rheumatologic diseases are rightfully concerned about the risk of flares after getting their COVID vaccines, especially after holding immune modulators,’ says says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘A new study is reassuring that flares are rare, even after holding or discontinuing immune modulators.’ The development of a vaccine for…

Filed under:ConditionsResearch Rheum Tagged with:COVID-19Flaresresearch reviewsvaccination

Flares Rare After COVID Vaccination

Catherine Kolonko  |  March 7, 2025

The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceResearch Rheum Tagged with:COVID-19flarevaccination

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences